Suven Life Sciences has secured a product patent each from African Regional Intellectual Property Organisation (Aripo) and South Korea corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The two patents are valid through 2033 and 2034, respectively, the company said in a BSE filing.
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
According to the company, the granted claims of the patents are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Parkinson and Schizophrenia.
The stock was trading 1 per cent higher at Rs 226.65 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
